N-Acetyl-L-Cysteine
Morton Neuroma
University of ArizonaPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Morton Neuroma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cntx-4975 Centrexion Therapeutics | Phase 2 | B |
Lopain National Institutes of Health Clinical Center (CC) | Phase 1 | CC |
Capsaicin Centrexion Therapeutics | Phase 1 | CC |
LIDOCAINE Oregon Health and Science University | Phase 1 | CC |
Xylocaine AstraZeneca | Early Phase 1 | CC |
LIDOCAINE Brown University | N/A | D |
Same molecule, other indications
N-Acetyl-L-Cysteine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →